Remission of functional motor symptoms following esketamine administration in a patient with treatment-resistant depression: a single-case report.
Journal
International clinical psychopharmacology
ISSN: 1473-5857
Titre abrégé: Int Clin Psychopharmacol
Pays: England
ID NLM: 8609061
Informations de publication
Date de publication:
01 01 2022
01 01 2022
Historique:
pubmed:
27
11
2021
medline:
11
3
2022
entrez:
26
11
2021
Statut:
ppublish
Résumé
Functional movement disorders (FMD) involve a broad range of abnormal involuntary movements not consistent with neurological diseases. These conditions often occur in combination with mood and anxiety disorders and are associated with poor clinical outcomes. We report the case of a 57-year-old woman diagnosed with treatment-resistant depression (TRD) and comorbid FMD treated with weekly intranasal administrations of esketamine over a six-month follow-up period. A comprehensive clinical and psychometric assessment was carried out at different time points. After 2 months of treatment, a complete remission of motor and axial functional disturbances (athetosis, trunk torsion and genuflections) was detectable, along with a progressive improvement in depressive symptoms during follow-up until full remission. According to novel lines of evidence, glutamatergic transmission might play a role in the pathophysiology of FMD through aberrant limbic-motor interactions. We report that treatment with esketamine, a noncompetitive N-methyl-d-aspartate glutamatergic receptor antagonist, was associated with remission of FMD symptoms in a patient with TRD. Pharmacological compounds modulating brain glutamatergic activity may be of potential benefit in the clinical management of FMD.
Identifiants
pubmed: 34825899
doi: 10.1097/YIC.0000000000000378
pii: 00004850-202201000-00004
doi:
Substances chimiques
Antidepressive Agents
0
Esketamine
50LFG02TXD
Ketamine
690G0D6V8H
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
21-24Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, et al. (Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 2019). 76:893–903.
Demartini B, Gambini O, Uggetti C, Cariati M, Cadioli M, Goeta D, et al. (Limbic neurochemical changes in patients with functional motor symptoms. Neurology 2019). 93:e52–e58.
Demartini B, Invernizzi RW, Campiglio L, Bocci T, D’Arrigo A, Arighi A, et al. (Cerebrospinal fluid glutamate changes in functional movement disorders. NPJ Parkinsons Dis 2020). 6:37.
Demartini B, Nisticò V, Edwards MJ, Gambini O, Priori AThe pathophysiology of functional movement disorders. Neurosci Biobehav Rev 2021). 120:387–400.
Feinstein A, Stergiopoulos V, Fine J, Lang AEPsychiatric outcome in patients with a psychogenic movement disorder: a prospective study. Neuropsychiatry Neuropsychol Behav Neurol 2001). 14:169–176.
Gelauff J, Stone J, Edwards M, Carson AThe prognosis of functional (psychogenic) motor symptoms: a systematic review. J Neurol Neurosurg Psychiatry 2014). 85:220–226.
Gupta A, Lang AEPsychogenic movement disorders. Curr Opin Neurol 2009). 22:430–436.
Heerlein K, Perugi G, Otte C, Frodl T, Degraeve G, Hagedoorn W, et al. (Real-world evidence from a European cohort study of patients with treatment resistant depression: treatment patterns and clinical outcomes. J Affect Disord 2021). 290:334–344.
Kranick S, Ekanayake V, Martinez V, Ameli R, Hallett M, Voon VPsychopathology and psychogenic movement disorders. Mov Disord 2011). 26:1844–1850.
Kranick SM, Moore JW, Yusuf N, Martinez VT, LaFaver K, Edwards MJ, et al. (Action-effect binding is decreased in motor conversion disorder: implications for sense of agency. Mov Disord 2013). 28:1110–1116.
McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, et al. (Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry 2021). 178:383–399.
Moore JW, Cambridge VC, Morgan H, Giorlando F, Adapa R, Fletcher PCTime, action and psychosis: using subjective time to investigate the effects of ketamine on sense of agency. Neuropsychologia 2013). 51:377–384.
Obhi SS, Swiderski KM, Farquhar RActivating memories of depression alters the experience of voluntary action. Exp Brain Res 2013). 229:497–506.
Parker RI, Vannest KJ, Davis JL, Sauber SBCombining nonoverlap and trend for single-case research: Tau-U. Behav Ther 2011). 42:284–299.
Pringsheim T, Edwards MFunctional movement disorders: five new things. Neurol Clin Pract 2017). 7:141–147.
Sar V, Akyüz G, Kundakçi T, Kiziltan E, Dogan OChildhood trauma, dissociation, and psychiatric comorbidity in patients with conversion disorder. Am J Psychiatry 2004). 161:2271–2276.
Thomsen BLC, Teodoro T, Edwards MJBiomarkers in functional movement disorders: a systematic review. J Neurol Neurosurg Psychiatry 2020). 91:1261–1269.
Turkoz I, Daly E, Singh J, Lin X, Tymofyeyev Y, Williamson D, et al. (Treatment response with esketamine nasal spray plus an oral antidepressant in patients with treatment-resistant depression without evidence of early response: a pooled post hoc analysis of the TRANSFORM studies. J Clin Psychiatry 2021). 82:20m13800.
Wajs E, Aluisio L, Holder R, Daly EJ, Lane R, Lim P, et al. (Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2). J Clin Psychiatry 2020). 81:19m12891.
Zheng W, Cai DB, Xiang YQ, Zheng W, Jiang WL, Sim K, et al. (Adjunctive intranasal esketamine for major depressive disorder: a systematic review of randomized double-blind controlled-placebo studies. J Affect Disord 2020). 265:63–70.